THOMAS FRANK E — SEC insider filings
SEC reporting owner CIK 1242616. 29 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2020-09-30 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 4 filings — 25,000 shares, $76,274 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
- Largest priced transaction: purchase of 5,000 shares @ $5.00 ($25,000) in Larimar Therapeutics, Inc., filed 2026-03-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | Director | 10 | 3 legs · 15,000 sh · $68,800 | — | 7 |
| Orchard Therapeutics plc (ORTX) | See Remarks | 10 | 1 leg · 10,000 sh · $7,474 | — | 40 |
| Spero Therapeutics, Inc. (SPRO) | Director | 9 | — | — | 10 |
Insider filings — THOMAS FRANK E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 8,000 @ $2.73 | EDGAR |
| 2026-06-25 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 5,000 @ $5 | EDGAR |
| 2025-06-16 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-05-14 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-02-15 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 2,000 @ $11 | EDGAR |
| 2024-01-24 | 4 | Orchard Therapeutics plc (ORTX) | Disposition to issuer (D): 92,081 · Disposition to issuer (D): 99,980 (derivative) @ $0 · Disposition to issuer (D): 199,990 (derivative) @ $0 · Disposition to issuer (D): 149,990 (derivative) @ $0 · Disposition to issuer (D): 309,990 (derivative) @ $0 · Disposition to issuer (D): 27,730 (derivative) @ $0 · +5 more | EDGAR |
| 2023-10-10 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2023-05-11 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | Orchard Therapeutics plc (ORTX) | Option exercise (M): 20,000 @ $0.46 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Orchard Therapeutics plc (ORTX) | Grant/award (A): 405,600 (derivative) @ $0 · Grant/award (A): 179,400 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Orchard Therapeutics plc (ORTX) | Option exercise (M): 20,000 @ $0.46 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2022-10-06 | 4 | Orchard Therapeutics plc (ORTX) | Disposition to issuer (D): 426,185 (derivative) @ $0 · Grant/award (A): 426,185 (derivative) @ $0 · Disposition to issuer (D): 184,229 (derivative) @ $0 · Grant/award (A): 184,229 (derivative) @ $0 · Disposition to issuer (D): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 · +10 more | EDGAR |
| 2022-09-19 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2022-06-03 | 4 | Orchard Therapeutics plc (ORTX) | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2022-05-12 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Orchard Therapeutics plc (ORTX) | Purchase (P): 10,000 @ $0.75 | EDGAR |
| 2022-01-07 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 2,214 (derivative) @ $9.03 | EDGAR |
| 2021-08-18 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Orchard Therapeutics plc (ORTX) | Grant/award (A): 27,731 (derivative) @ $0 · Grant/award (A): 310,000 (derivative) @ $0 | EDGAR |
| 2021-02-01 | 4 | Orchard Therapeutics plc (ORTX) | Option exercise (M): 10,000 @ $2.44 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Orchard Therapeutics plc (ORTX) | Grant/award (A): 10,667 @ $0 · Tax withholding (F): 3,706 @ $6.72 | EDGAR |
| 2021-01-06 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 1,314 (derivative) @ $13.31 | EDGAR |
| 2020-10-27 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2020-09-30 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 16,600 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1242616 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs